ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Avigan maker Fujifilm faces China military risk to patent

Approval doubts threaten health care ambitions of Japanese company

The Japanese health ministry is currently weighing approval of Avigan as a COVID-19 treatment. (Source photos by Tomoki Mera and Takaki Kashiwabara) 

TOKYO -- Fujifilm Holdings has warned the Japanese government that a research arm of the Chinese military may claim intellectual property rights over the anti-flu drug Avigan as a COVID-19 treatment.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more